leky-latky/pea/protizanetlive

Lung inflammation by SARS-CoV-2 infection

• Company called FSD Pharma
• PEA into a Phase 1 clinical trial under the name FSD-201
• Has approval from the FDA for progressing to Phase 2a for this indication

Protizánětlivé

2013, a metareview was published on the clinical efficacy and safety of PEA in the treatment of the common cold and influenza

• Six double-blind, placebo, randomized controlled trials